Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Oct 28 - Nov 2
Trial Metric Retatrutide 12mg (TRIUMPH-4) Semaglutide 2.4mg (STEP 1) Mean Weight Loss 28.7% at 68 weeks 14.9% at 68 weeks Mechanism Triple agonist (GLP-1/GIP/GCGR) Single agonist (GLP-1) FDA Status Phase 3 (investigational) Approved (Wegovy) Dosing Weekly subcutaneous Weekly subcutaneous Common Adverse Events GI (nausea, vomiting, diarrhea), dysesthesia GI (nausea, vomiting, diarrhea) Important caveat: These results come from different trial populations and study designs
Understanding proper switching protocols helps maintain therapeutic effect and minimize disruption
Against injectable tirzepatide, orforglipron loses
The appeal of a lower price is understandable, especially when retatrutide costs significantly more than simpler peptides
Comparing effects of a low-energy diet and a high-protein low-fat diet on sexual and endothelial function, urinary tract symptoms, and inflammation in obese diabetic men
Common Mistakes When Using the Calculator Although the calculator handles the math automatically, small errors in data entry or interpretation can lead to confusion
:format(webp))
US$ 23.16
US$ 29.28
US$ 26.76
